Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
Qingqing Pan, Xinxin Cao, Yaping Luo, Li J, Fang Li
Abstract
Abstract Purpose 68 Ga-pentixafor PET/CT was reported to have a high sensitivity in detecting tumor involvement of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in our previous study. We aimed to further investigate the semi-quantitative measurements of 68 Ga-pentixafor PET/CT in response assessment in WM/LPL. Methods Fifteen patients with WM/LPL were recruited in a prospective cohort study and underwent both 68 Ga-pentixafor and 18 F-FDG PET/CT at baseline and post-treatment. PET/CT-based responses were analyzed with semi-quantitative assessments of metabolic tumor volume (MTV) and total lesions glycolysis/uptake (TLG FDG and TLU CXCR4 ), and the correlation between PET/CT-based response and clinical response, monoclonal protein and IgM response was analyzed. Results After chemotherapy, 5 patients had complete response or very good partial response, 8 had partial response or minimal response and 2 had progressive disease. In quantitative analysis, 68 Ga-pentixafor PET/CT-based response (measured in ∆TLU CXCR4 %, ∆MTV CXCR4 %, ∆SUVpeak%) showed a significant direct correlation with clinical response, monoclonal protein and IgM response ( p < 0.01). However, 18 F-FDG PET/CT-based response was independent from clinical response ( p > 0.05). Conclusions The semi-quantitative measurements of 68 Ga-pentixafor PET/CT outperformed 18 F-FDG PET/CT in response assessment of WM/LPL.